Business
Rakovina Therapeutics to Present New Data Highlighting CNS-Penetrant ATR and PARP1 Inhibitors at the 2025 Society for Neuro-Oncology Annual Meeting
VANCOUVER, British Columbia, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (ȁ...
About this update from Rakovina Therapeutics Inc
[{"type":"text","content":"Rakovina Therapeutics to Present New Data Highlighting CNS-Penetrant ATR and PARP1 Inhibitors at the 2025 Society for Neuro-Oncology Annual Meeting\n\n\n\n VANCOUVER, British Columbia, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV)(FSE: 7JO0) a biopharmaceutical company advancing cancer therapies through AI-enabled drug discovery, today announced that new data will be presented in two posters at the Society for Neuro-Oncology (SNO) Annual Meeting, taking place November 19–23, 2025, in Honolulu, Hawaii.\n \n\n The presentations will highlight Rakovina’s AI-driven programs to discover and develop next-generation DNA-damage response (DDR) inhibitors engineered for central nervous system (CNS) penetration, supporting the development of potential new treatment options for primary and metastatic brain cancers.\n \n\n Presentation Details:\n \n\n Title:\n \n\n Discovery and development of a novel CNS-penetrating ATR inhibitor\n \n\n\n Session: Poster Session – DNA Repair (DNAR-05)\n \n Date/Time: November 21, 2025 | 11:30 a.m.–12:45 p.m. (HST)\n \n\n Title:\n \n\n Discovery and development of novel CNS-penetrating PARP1-selective inhibitors\n \n\n\n Session: Poster Session – DNA Repair (DNAR-06)\n \n Date/Time: November 21, 2025 | 11:30 a.m.–12:45 p.m. (HST)\n \n\n The first poster presents results from Rakovina Therapeutics’ kt-5000AI ATR inhibitor program, developed in collaboration with Variational AI. The program leverages the ENKI™ generative AI platform to design and optimize CNS-penetrant ATR inhibitors with favorable pharmacologic properties for the potential treatment of brain cancers. The data highlight the discovery of potent, selective ATR inhibitors that demonstrate activity against treatment-resistant tumor phenotypes.\n \n\n The second poster presents progress from the Company’s kt-2000AI PARP inhibitor program, developed using the Deep Docking™ AI-accelerated drug discovery platform. The program applies ultra-large-scale virtual screening to evaluate billions of compounds in silico, rapidly identifying and optimizing PARP1-selective, CNS-penetrant inhibitors with desirable pharmacologic properties. The data illustrate how this approach enables deep exploration of chem...